Sbir phase i topic 352 cell-based models for prostate cancer health disparity research

Ended Definitive Contract Awarded

Contract number
HHSN261201600038C
Awardee
Awarding agency
Obligated
$224,687

Award facts

Opportunity
  • N43CO6100926 Solicitation number
Contract value 100% obligated
$224,687.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
541990 All Other Professional, Scientific, and Technical Services
PSC
AN11 Health R&D Services; Health Care Services; Basic Research
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Rockville, MD 20850, USA

Award details come from SAM.gov/FPDS.

About this award

The National Cancer Institute (NCI), a civilian federal agency, awarded a Small Business Innovation Research (SBIR) Phase I contract to Shuttle Pharmaceuticals, Inc., a for-profit subchapter S corporation. The $224,687.00 firm-fixed-price contract, awarded on September 19, 2016, is for the SBIR PHASE I TOPIC 352 CELL-BASED MODELS FOR PROSTATE CANCER HEALTH DISPARITY RESEARCH project, with a planned completion date of June 18, 2017. This contract was set aside for small businesses.

Quick answers

Who was awarded contract HHSN261201600038C?

HHSN261201600038C was awarded to Shuttle Pharmaceuticals, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2016.

How much is contract HHSN261201600038C worth?

The government has obligated $224,687 on HHSN261201600038C.

Was contract HHSN261201600038C competed?

The extent of competition for HHSN261201600038C was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award